🇪🇺 Dexamethasone Sodium Phosphate in European Union

Dexamethasone Sodium Phosphate (dexamethasone phosphate) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005740
  • Marketing authorisation holder: Taw Pharma (Ireland) Ltd
  • Local brand name: Dexamethasone Taw
  • Indication: Indicated for cerebral oedema, post-traumatic shock-lung syndrome, asthma, skin diseases, autoimmune diseases, rheumatoid arthritis, prophylaxis and treatment of post-operative or cytostatic-induced vomiting, treatment of COVID-19, eye inflammation and infection.
  • Status: withdrawn

Read official source →

Dexamethasone Sodium Phosphate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Dexamethasone Sodium Phosphate approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Dexamethasone Sodium Phosphate in European Union?

Taw Pharma (Ireland) Ltd holds the EU marketing authorisation.